title: Radionuclide assessment of blood-brain barrier disruption performed for chemotherapy of high grade malignant brain gliomas.
abstract: Compared to the conventional mode of chemotherapy of malignant brain gliomas following surgery and radiation therapy, chemotherapy after transient disruption of the blood-brain barrier coupled with intraarterial administration of methotrexate improved median survival from 12-14 to 22 months in our experience. Technetium-99m-DTPA brain scintigraphy played a unique and important role in the documentation of optimum blood-brain barrier disruption. Patients with excellent clinical outcome had significantly (P less than 0.0005) better blood-brain barrier disruption than patients with poor outcome. The results indicate that the clinical outcome is related to the degree of blood-brain barrier disruption.
authors.affiliation: Department of Radiology (Nuclear Medicine), University of Missouri Hospital and Clinics, Columbia 65212.
authors.forename: A
authors.initials: A
authors.lastname: Singh
authors.forename: B D
authors.initials: BD
authors.lastname: Belshe
authors.forename: M K
authors.initials: MK
authors.lastname: Gumerlock
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001812:Blood-Brain Barrier / Q000187:drug effects*; D001932:Brain Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy; D002648:Child; D005260:Female; D005910:Glioma / Q000000981:diagnostic imaging* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D016284:Technetium Tc 99m Pentetate; D014057:Tomography, X-Ray Computed
chemical_list: D016284:Technetium Tc 99m Pentetate